High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
A recent study demonstrated the association between inflammation, iron metabolism and fibroblast growth factor (FGF) 23. The present clinical study aimed to assess associations between anemia, iron metabolism and FGF23 in hemodialysis (HD) patients. This prospective observational study examined a cohort of prevalent HD patients (n = 282). Blood samples were obtained before dialysis sessions to measure baseline levels of hemoglobin (Hb), transferrin saturation (TSAT), ferritin, albumin-adjusted calcium (Ca), phosphate (P), intact (i)-PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact (i)-FGF23, high sensitive (hs)-CRP, and interleukin-6. After the baseline measurement, study patients were followed-up for 6 months. Biochemical measurements were subsequently performed at 1 (Hb), 2 (TSAT and ferritin) or 3 (Ca, P and hs-CRP) month intervals. Doses of ESAs and intravenous iron supplementation during the study period were recorded. i-FGF23 was positively correlated with Ca, P, i-PTH and inversely correlated with TSAT and ferritin. However, levels of Hb and hs-CRP and doses of ESAs during the study period did not differ among the i-FGF23 tertiles, with levels of ferritin and TSAT in the higher i-FGF23 tertile being consistently lower than in the middle to lower i-FGF23 tertiles. Multivariate repeated measures analysis indicated that the higher i-FGF23 tertile was independently associated with repeated measurements of ferritin, but not of TSAT. Doses of intravenous iron supplementation were significantly increased in the higher i-FGF23 tertile in multivariate models. In conclusion, high i-FGF23 levels may be associated with prolongation of low levels of ferritin, resulting in increased usages of iron supplementation in HD patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients
- Date Crossref
- 05/05/2017
- Éditeur
- Public Library of Science (PLoS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
SHOWA Medical University pays non établi dans la noticeUniversité ou école supérieure
-
SHOWA Medical University Koto Toyosu Hospital pays non établi dans la noticeÉtablissement de santé
-
Ebara (Japan) pays non établi dans la noticeEntreprise
-
Kawasaki Hospital pays non établi dans la noticeÉtablissement de santé
-
SHOWA Medical University Northern Yokohama Hospital pays non établi dans la noticeÉtablissement de santé
-
Showa University Koto Toyosu Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Ebara Clinic pays non établi dans la noticeÉtablissement de santé
-
Kawasaki Clinic pays non établi dans la noticeÉtablissement de santé
-
Kitami Higashiyama Clinic Division of Dialysis pays non établi dans la noticeÉtablissement de santé
-
Showa University Northern Yokohama Hospital pays non établi dans la noticeUniversité ou école supérieure
SHOWA Medical University, SHOWA Medical University Koto Toyosu Hospital et Ebara (Japan), avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.